Exact Sciences Corp

EXAS

Equity

ISIN US30063P1057 / Valor 1183218

NASDAQ (2024-09-17)

USD 67.99-2.14%

Exact Sciences Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Exact Sciences Corp is a biotechnology company that focuses on developing non-invasive screening tests for early detection of cancer. One of its key products is Cologuard, which is an FDA-approved screening test for colorectal cancer. The company has also received proposed coverage from the Centers for Medicare and Medicaid Services (CMS) for its products. Exact Sciences Corp is known for its innovative approach to cancer screening and its commitment to improving patient outcomes through early detection.

Summarized from source with an LLMView SourceSector: Technology

Total Revenue

Exact Sciences Corp. reported total revenue of $699 million for the second quarter of 2024, marking a 12% increase compared to the same period in 2023. This growth was driven by strong performance across its product lines.

Screening Revenue

In the second quarter of 2024, Exact Sciences Corp. achieved screening revenue of $532 million, which represents a 15% increase from the previous year. This growth was primarily fueled by the increased adoption of the Cologuard test.

Precision Oncology Revenue

Exact Sciences Corp.'s precision oncology revenue reached $168 million in the second quarter of 2024, showing a 7% increase year-over-year. This segment includes revenue from global Oncotype DX and therapy selection tests.

Net Loss Improvement

For the second quarter of 2024, Exact Sciences Corp. reported a net loss of $16 million, or $0.09 per share. This is a significant improvement of $65 million and $0.36 per share compared to the same period in 2023.

Adjusted EBITDA

Exact Sciences Corp. reported an adjusted EBITDA of $110 million for the second quarter of 2024, an increase of $43 million from the previous year. The adjusted EBITDA margin also improved by 500 basis points to 16%.

Summarized from source with an LLMView Source

Key figures

-11.3%1Y

-37.1%3Y

-36.4%5Y

Performance

54.0%1Y

58.2%3Y

60.3%5Y

Volatility